Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children's Hospital of Pittsburgh developed a new way to profile brain cancers in children, paving ...

A team of international scientists has developed a method to predict the risk of developing cancer from a blood disorder common in older adults, according to a study published in the journal Blood.

The Car-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system.

Men who had given blood more than 100 times in their life were more likely to have blood cells carrying certain beneficial ...

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...

A recent case report describes a 63-year-old woman in China who was diagnosed with a rare variant of the RhD antigen.

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...